TRIP4: A Protein with Potential as A Drug Target Or Biomarker

Target Name: TRIP4

NCBI ID: G9325

TRIP4

TRIP4: A Protein with Potential as A Drug Target Or Biomarker

TRIP4, short for Activating Signal Cointegrator 1, is a protein that plays a critical role in the regulation of cell signaling pathways. Discovered in 2012, TRIP4 has since been shown to be involved in a wide range of physiological processes, including cell growth, differentiation , and metabolism. As a result, it has potential as a drug target or biomarker.

The protein TRIP4 is named after its unique structure, which consists of four distinct domains: a N-terminal transmembrane domain, a coiled-coil domain, a catalytic domain, and a C-terminal T-loop domain. The N-terminal transmembrane domain gives TRIP4 its unique ability to interact with various signaling molecules, while the coiled-coil domain and T-loop domain are involved in the protein's stability and function.

One of TRIP4's most significant functions is its role in the regulation of cell signaling pathways. It has been shown to play a critical role in the regulation of cell growth, differentiation, and metabolism. For example, TRIP4 has been shown to be involved in the regulation of cell proliferation, and has been shown to interact with the protein transmembrane integrin (integrin) in a way that regulates cell migration.

In addition to its role in cell signaling pathways, TRIP4 has also been shown to play a critical role in the regulation of cellular stress responses. It has been shown to play a key role in the regulation of cellular stress responses, and has been shown to interact with the protein component 7 (component 7) in a way that regulates stress responses.

TRIP4 has also been shown to play a critical role in the regulation of cellular immune responses. It has been shown to interact with the protein PD-L1 (PD-L1) in a way that regulates immune responses, and has been shown to play a key role in the regulation of T-cell responses.

As a result of its involvement in so many critical cellular processes, TRIP4 has great potential as a drug target or biomarker. Its ability to interact with a wide range of signaling molecules and its involvement in cell signaling pathways, stress responses, and immune responses make it an attractive target for both research and development.

TRIP4 has also been shown to be a good candidate for biomarker discovery. Its unique structure and its involvement in a wide range of cellular processes make it an attractive candidate for manipulation with drugs or other therapeutic agents. This could lead to new treatments for a wide range of diseases, including cancer, metabolism, and immune disorders.

In conclusion, TRIP4 is a protein with great potential as a drug target or biomarker. Its unique structure and its involvement in a wide range of cellular processes make it an attractive candidate for manipulation with drugs or other therapeutic agents. Further research is needed to fully understand its functions and its potential as a therapeutic agent.

Protein Name: Thyroid Hormone Receptor Interactor 4

Functions: Transcription coactivator which associates with nuclear receptors, transcriptional coactivators including EP300, CREBBP and NCOA1, and basal transcription factors like TBP and TFIIA to facilitate nuclear receptors-mediated transcription. May thereby play an important role in establishing distinct coactivator complexes under different cellular conditions. Plays a role in thyroid hormone receptor and estrogen receptor transactivation (PubMed:10454579, PubMed:25219498). Also involved in androgen receptor transactivation (By similarity). Plays a pivotal role in the transactivation of NF-kappa-B, SRF and AP1. Acts as a mediator of transrepression between nuclear receptor and either AP1 or NF-kappa-B (PubMed:12077347). May play a role in the development of neuromuscular junction (PubMed:26924529). May play a role in late myogenic differentiation (By similarity). Also functions as part of the RQC trigger (RQT) complex that activates the ribosome quality control (RQC) pathway, a pathway that degrades nascent peptide chains during problematic translation (PubMed:32099016)

The "TRIP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets